Introduction
Among the plant-derived compounds that have been linked to the chemoprevention and treatment of cancer, the flavonoids occupy a special place due to their abundance in human food and their relative non toxicity (Havsteen, 2002; Lopez-Lazaro, 2002; Middleton, Jr. et al., 2000; Surh, 2003) . 50
In a program aimed at finding new antiangiogenic agents in the flavonoid family, we have recently identified the natural flavonoid fisetin (3,3',4',7-tetrahydroxyflavone) as an interesting lead that can stabilize endothelial cells in vitro at non cytotoxic concentrations (Touil et al., 2009) . Fisetin is found in several fruits, vegetables, nuts and wine (Arai et al., 2000; Kimira et al., 1998) and displays a variety of biological effects including antioxidant, 55
anti-inflammatory (Park et al., 2007; Woodman and Chan, 2004) , anti-carcinogenic and in vitro anti-angiogenesis (Fotsis et al., 1997) . Fisetin has been shown to inhibit several molecular targets, including cyclin-dependent kinases (Lu et al., 2005a; Lu et al., 2005b; Sung et al., 2007) , DNA topoisomerases I and II (Constantinou et al., 1995; Olaharski et al., 2005) , urokinase (Jankun et al., 2006) , actin polymerization (Böhl et al., 2007) , and androgen 60 receptor signalling (Khan et al., 2008) .
In vivo, fisetin has recently been shown to possess interesting anticancer activity in mice bearing lung carcinoma (Touil et al., 2011) , prostate tumours (Khan et al., 2008) , and human embryonal carcinoma (Tripathi et al., 2011) . Its in vivo mechanism of action appears rather complex and includes antiangiogenic, antiandrogenic and anti-metastatic activities 65 (Chien et al., 2010; Khan et al., 2008; Touil et al., 2011; Tripathi et al., 2011) .
Despite its highly interesting properties for cancer therapy, fisetin administration in vivo remains problematic partly due to its poor water solubility (Guzzo et al., 2006; Mignet et al., 2012) . Fisetin bioavailability must therefore be significantly improved in order to optimize its delivery to tumours after in vivo administration. Although the design of suitableA c c e p t e d M a n u s c r i p t 4 molecular carriers for flavonoids is an area of intense research, solutions are still far from being developed for therapy, and suitable molecular carriers for flavonoids have yet to be designed and tested (Leonarduzzi et al., 2010) . To do so, we therefore chose to formulate fisetin into nanoemulsion in order to hopefully achieve a better bioavailability.
Nanoemulsions represent good vehicles to formulate hydrophobic active molecules 75 (Sarker, 2005) . For example, nanoemulsions are widely used for parenteral administration of lipids, and have also been employed for intravenous administration of anticancer drugs like paclitaxel (Kan et al., 1999) and chlorambucil (Ganta et al., 2008) . Also noteworthy, nanoemulsion has also been recently reported to contribute to the in vivo increase in efficacy of anticancer drugs, e.g., dacarbazine (Tagne et al., 2008) and camptothecin (Han et al., 80 2009 ).
The aim of the present study was therefore to design and characterize a nanoemulsion of fisetin that could be suitable for parenteral administration. We also evaluated the fisetin nanoemulsion pharmacokinetics after intravenous (i.v.) or intraperitoneal (i.p.) administration in mice, and determined its relative i.p. bioavailability compared to the i.p. administration of 85 the free fisetin. Finally, the antitumour activity of the fisetin nanoemulsion was compared to the administration of free fisetin in Lewis lung carcinoma bearing mice. The other chemicals used for drug dissolution, plasma preparation and HPLC analysis were the following: methanol, acetonitrile, perchloric acid (Carlo Erba Reactif SDS, Peypin, France); DMSO, PEG 200, morin, phosphate buffer (pH 7.4) and mouse serum (Sigmainserm-00709735, version 1 -19 Jun 2012 A c c e p t e d M a n u s c r i p t 6 Aldrich, Saint Quentin Fallavier, France). All other chemicals were of pharmaceutical grade or of the highest analytical purity available. 115
Fisetin solubility studies
Fisetin solubility was assessed according to the approached solubility method (Mulak and Cotty, 1975) . Fisetin solubility was first separately assessed in different oil phases and 120 surfactants, and thereafter in various mixtures of oil/surfactant (Tables 1-3 ). Increasing fisetin concentrations were introduced in the various phases under agitation and heating at 60  2°C until a precipitate was observed. The solubility was determined after cooling at room temperature. Emulsification was accomplished by phase inversion (Becher, 1965) , i.e., the aqueous phase was added to the oil phase. The mixture was then submitted to a high shear mixer (Ultraturrax ® T25 , Ika, Staufen, Germany) for 10 min at 21,500 rpm (set at 5) that allowed the formation of a crude emulsion. An additional 15 min sonication in the cold of the previous 135 emulsion using a Sonifier ® 450 set at 90% and output 3 allowed to obtain a submicron emulsion. For intravenous (i.v.) and intraperitoneal (i.p.) administration, sodium hydroxide 0.1 N was used to adjust pH to 7.0 and glycerol 2.25% was added to adjust tonicity. Two 
Nanoemulsion characterization and stability studies
Nanoemulsions were visually inspected for eventual creaming, coalescence, phase separation and/or precipitation. After dilution (1/1000) in water, the mean droplet size, size 145 distribution, the zeta potential (), and the polydispersity index (PDI) were determined using a Zetasizer Nano ZS (Malvern Instruments, Orsay, France). The PDI reflects the polydispersity of the emulsion ranging from 0 to 1, with lower values indicating a more monodispersed suspension. pH was determined using a pH meter 210 (MeterLab, Copenhagen, Denmark). A short term stability of the optimized formulations over a period of 30 days was accomplished 150 at room temperature (+20  2°C) and at +4°C by evaluating the above mentioned parameters.
Measurements were performed in triplicate.
For the determination of the fisetin concentration, nanoemulsions were diluted (1/2000) in methanol, vortexed, and 100 µL were injected onto a reversed-phase HPLC system (Shimadzu CLASS-VP ® , version 5.3), equipped with an octadecylsilane column 155 (Beckman Ultrasphere ODS, 5 µm; 4.6  250 mm) thermostated at 20°C, and a UV detector set at 360 nm. The mobile phase was composed of 25% acetonitrile and 75% acidified water (2% v/v glacial acetic acid), at a flow rate of 1 mL/min. In these conditions the retention time of fisetin was 8 min. The area of the fisetin peak was reported to a calibration curve to determine the concentration of fisetin. Calibration curves were linear with correlation 160 coefficients near unity. (Edgell et al., 1983) were grown in 165 DMEM containing 2 mM L-glutamine, 10% foetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin (37°C, 5% CO 2 ). Cells were plated onto 96-well plates at 5000 cells per well in 100 µL of culture medium. The fisetin-free nanoemulsion or the fisetin nanoemulsion were added to the cells for a 2 h exposure time, and the cell morphology was assessed under microscopy at a magnification of X100 (Nikon Diaphot, Nikon Corp. Japan). of 40 µL. It should be noted that an undiluted DMSO volume of 50 µL can be administered safely i.v. to mice without toxicity (Willson et al., 1965) , and that in our studies, the final DMSO dose per mouse corresponds to 40 µL (for a 20 g mouse), which was further diluted in saline and injected slowly over 1 minute. We did not encounter any acute mortality using this formulation in our studies. 
Effect of fisetin nanoemulsion on endothelial cells

Determination of fisetin concentration in plasma 200
Fisetin concentration in plasma was determined by HPLC as followed: to 100 µL of plasma was added 60 µL of a morin methanolic solution at 0.5 mg/mL (internal standard), and 200 µL of cold acidified methanol (methanol:perchloric acid 70%, 200:1, v:v) to precipitate proteins. After vortexing for 5 min the samples were kept on ice for 15 min, and centrifuged at 10,000  g at 4°C. The supernatant (100 µL) was injected onto a reversed-phase HPLC 205 system as described above with the UV detector set at 360 nm. The ratio of the area of the fisetin peak divided by the internal standard peak area was reported to a calibration curve to determine the concentration of fisetin. Calibration curves were linear with correlation coefficients near unity. The quantification limit of the system was 0.1 µg/mL. 210
Pharmacokinetic parameters determination
The following non compartmental pharmacokinetic parameters were calculated using standard methods (Gibaldi and Perrier, 1982) : maximum concentration (C max ) extrapolated to 
Evaluation of antitumour activity in mice 225
Female 8 weeks old C57BL/6J mice (body weight 18-22 g) (Janvier, Le Genest-StIsle, France) were used for antitumour evaluation. Lewis lung tumour fragments (about 2 mm diameter) were implanted subcutaneously (s.c.) bilaterally into mouse flanks using a 12 gauge trocar. Four days after tumour implantation, the mice were submitted to the following i.p. treatments (4 mice per group) for 12 consecutive days (day 4 to 15): 4 control mice received a 230 fisetin-free nanoemulsion; 4 mice received the fisetin nanoemulsion corresponding to 18.3 mg/kg of fisetin; and, 4 mice were injected the fisetin nanoemulsion at 36.6 mg/kg. Tumour growth was assessed using caliper bi-dimensional measurements (in mm) and the tumour volume (mm 3 ) was calculated according to the following formula: (width 2  length/2). Table 1 presents the solubility of fisetin in various solvents. Fisetin was not soluble in water (<1 mg/g) and was weakly soluble in ethanol (<14 mg/g). Fisetin was also found weakly soluble for all the oil phases tested, with a maximum solubility value < 6 mg/g for 245 triacetin and < 5 mg/g for propylene glycol monocaprylate. Table 2 shows fisetin solubility in frequently used surfactants. In lipophilic surfactants (low HLB value), fisetin solubility was low, whereas its solubility was markedly increased in hydrophilic surfactants with high HLB values. The best surfactant was found to be Labrasol 
Fisetin solubility in various solvents
Development of a fisetin nanoemulsion
Emulsification capacity
Several nanoemulsion formulations were thereafter tested for their emulsification capacity and 3 cases could be observed, as follows (Table 4) 
Fisetin incorporation into nanoemulsion formulations
We have next evaluated the maximum quantity of fisetin that could be incorporated into each nanoemulsion (formulations 1, 8, 9), or solution (formulation 10). Table 4 shows that formulation 1 could incorporate only 1 mg/g of fisetin, whereas formulations 8 and 9 allowed the incorporation of 5 mg/g of the flavonoid. These formulations were found visually 270 stable on day 1. Although formulation 10 allowed to solubilize up to 16 mg/g of fisetin due to its higher content in Labrasol ® and Tween ® 80, it was unfortunately found to precipitate on day 1 for concentrations of 8 and 16 mg/g, but was found stable for a fisetin concentration of 4 mg/g. 
Choice of final fisetin nanoemulsion formulation
Considering the above results, formulations 8 and 9 were therefore considered a good compromise between fisetin content and nanoemulsion stability. These formulations were further tested for their particle diameter and polydispersity index (PDI) and it was observed that preparation 8 containing soybean oil yielded a nanoparticle diameter of 323  2 nm with 280 a PDI of 0.153, whereas preparation 9 containing Miglyol 812 N showed a nanoparticles diameter of 146  3 nm and a PDI of 0.015. Formulation 9 was therefore chosen for further in vitro and in vivo testing because of its good fisetin content, its nanoparticle size and low PDI value. The final composition of nanoemulsion 9 containing 5 mg/ml of fisetin was therefore as follows: Miglyol 812 N (10%), Labrasol ® (10%), Tween ® 80 (2.5%), Lipoid E80 ® 285
(1.2%), glycerol (2.25%), NaOH (0.1N) to adjust to pH 7, water to 100%.
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Stability of the fisetin nanoemulsion
We next performed short term stability studies of the fisetin nanoemulsion 290 (preparation 9) over a period of 30 days at room temperature (20°C) and at 4°C (Table 5) by evaluating particle diameter, pH, zeta potential and the PDI.
Droplet size of nanoemulsion 9 stored at 20°C increased markedly as a function of time until phase separation occurred on day 30, whereas for the 4°C storage condition, particle diameter remained relatively stable for the 30 day examination period. A slight 295 decrease in pH was noted at both storage temperatures. For the zeta potential, negative values were observed and remained stable over 30 days for the 4°C storage condition. The PDI presented an important increase over time at 20°C, whereas it was found stable and relatively low at 4°C. In order to be administered via parenteral routes, we also checked if the nanoemulsion could sustain standard steam sterilization conditions (121°C for 15 min) but 300 this resulted in phase separation. However, sterilization of nanoemulsion 9 has been successfully carried out using a 0.22 µm filter with preservation of homogeneity and size characteristics.
Effect of fisetin nanoemulsion on endothelial cells 305
Free fisetin has been reported to exert a distinct morphological effect on endothelial cells that is characterized by the rapid development of pseudopods at non cytotoxic concentrations (Touil et al., 2009 ). We therefore tested if the fisetin nanoemulsion (preparation 9) could exert the same morphological effects on Eahy 926 endothelial cells to 310 verify if the active principle is indeed released from the pharmaceutical preparation. A c c e p t e d M a n u s c r i p t 14 appearance, whereas exposure to free fisetin led to the expected pseudopods formation (Figure 1-B) . Endothelial cells exposed to control nanoemulsion without fisetin resemble normal control endothelial cells (Figure 1-C) , whereas the pseudopods are indeed observed in 315 the cells exposed to the fisetin nanoemulsion (Figure 1-D) . This observation indicates that fisetin is indeed released from the nanoemulsion and can exert similar morphological effects as the free fisetin on endothelial cells.
Fisetin nanoemulsion pharmacokinetics in mice 320
The developed fisetin nanoemulsion (preparation 9) was next administered in vivo to evaluate its pharmacokinetics in mice. We first examined the intravenous route (i.v.) by injecting the free fisetin formulation or its nanoemulsion at a dose of 13 mg/kg. We noted a very similar pharmacokinetic profile between the two formulations with plasma 325 concentrations versus time curves almost superimposable (Figure 2) . Indeed, similar pharmacokinetic parameters in terms of Cmax, AUC and terminal half-life were observed for both formulations (Table 6 ). The i.v. route administration of the fisetin nanoemulsion was however found relatively toxic, because we noted a mortality rate of 3/21 mice (14%), apparently due to the rapid administration. 330
In order to avoid the acute toxicity of the i.v. administration, we next explored the intraperitoneal (i.p.) route. For the fisetin nanoemulsion, a comparison of its pharmacokinetics after i.p. administration with the free fisetin injected by the same route is presented in Figure   3 . Compared to the i.p. administration of the free fisetin, it can be seen that the injection of the fisetin nanoemulsion led to a significant increase in fisetin plasma concentrations, even at a 335 fisetin nanoemulsion dose (112.5 mg/kg) half that of the free fisetin dose (223 mg/kg). The pharmacokinetic parameters presented in Table 6 indicate that not only the maximum plasma A c c e p t e d M a n u s c r i p t 15 concentrations reached were higher for the nanoemulsion, but the relative bioavailability was 24-fold higher compared to the free fisetin. This increase in bioavailability with the nanoemulsion appears to be due to a faster absorption with this drug formulation as shown by 340 a shorter mean absorption time (MAT) of 1.97 h compared to 5.98 h for the free fisetin. It is also noteworthy that following the i.p. administration of the fisetin nanoemulsion, no mortality was observed.
Fisetin nanoemulsion antitumour activity in mice 345
We were next interested to evaluate the antitumour activity of the developed fisetin 
Discussion
355
The main objectives of this study was to develop a nanoemulsion of the hydrophobic flavonoid fisetin, determine its pharmacokinetics in mice, and evaluate its anticancer activity in vivo. The first problems encountered were the low fisetin solubility in the classical oil phases usually employed in formulation, e.g., soybean oil or medium chain triglycerides (Date 360 and Nagarsenker, 2008). The best solubility was observed with triacetin, a short chain triglyceride composed of triester of glycerol and acetic acid. However, triacetin does not exhibit remarkable emulsifying properties (Poullain-Termeau et al., 2008) . Fisetin was also found weakly soluble in lipophilic surfactants, but was more soluble in hydrophilic surfactants. As a matter of fact, the maximum solubility was observed with Labrasol ® , a 365 mixture of triglycerides and polyethylene glycol esters possessing a hydrophilic-lipophilic balance of 14. We did not observe any synergistic effect between the oil phase and surfactant, be it hydrophilic or lipophilic. Hence, the fisetin low solubility in lipid phases leads to a weak association of the active principle in this phase and therefore requires more solubilising surfactant, as previously reported for a nanoemulsion of carbamazepine (Kelmann et al., 370 2007) . We finally found that the best mixture was the one composed of Labrasol ® /Tween ® 80 which allowed to achieve an acceptable fisetin concentration of 5 mg/ml.
Although Labrasol ® has already been employed in injectable preparations (Nornoo et al., 2008) , no standard preparation has been developed so far, to our knowledge, with this proprietary formulation. Labrasol ® is mostly used in auto-emulsifying systems for oral 375 administration (Kommuru et al., 2001) and it has been shown to increase oral absorption of hydrophilic drugs, e.g., gentamicin (Hu et al., 2001) . Available toxicity data on Labrasol ® show that it is relatively non toxic when given orally to rats with a LD50 of 22 g/kg (Gad et al., 2006) . However, acute toxicity data are not available for the intravenous or intraperitoneal
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Page 18 of 40 A c c e p t e d M a n u s c r i p t 17 routes. In our experiments, a mortality rate of 14% was noted for the i.v. route, whereas no 380 mortality was observed for the i.p. route. The other components of the nanoemulsion are not likely to contribute to acute toxicity because medium chain triglycerides (e.g., Miglyol 812 N) and lecithins are already widely used in injectable preparations. Tween ® 80 can also be ruled out in this toxicity because it is frequently used at high concentrations, e.g., 25% in docetaxel preparation without apparent toxicity (Strickley, 2004) . Therefore, a compromise 385 will have to be found between the toxicity of the excipient and the final concentration in fisetin.
With regard to the physico-chemical properties of the fisetin nanoemulsion, it was found that the preparation containing Miglyol 812 N (No. 9) showed acceptable fisetin content, nanoparticle size and PDI. This fisetin nanoemulsion was found to be unstable at 390 room temperature with increasing diameter and PDI values over time, with phase separation occurring on day 30. This relatively slow process could be explained by the Ostwald ripening in which larger particles grow at the expense of smaller ones due to the higher solubility of the smaller particles and to molecular diffusion through the continuous phase (Capek, 2004) .
This phenomenon finally ends up in the coalescence of the emulsion (Tadros et al., 2004) . 395
Because this phenomenon is temperature sensitive, it was noted that nanoemulsions kept at 4°C were remarkably stable with almost unchanged particle diameter and PDI over the 30 day examination period. PDI smaller that 0.250 are considered acceptable for parenteral preparations (Müller et al., 2004) . However, it was also noted, as expected, that the nanoemulsion was particularly unstable in steam sterilization conditions (121°C, 15 min) 400 probably due to the non-ionic surface active agents which are not stable at high temperatures (Nornoo et al., 2008) . To overcome this problem, sterilization by filtration could therefore be employed for nanoemulsions (Floyd, 1999) . The formulated fisetin nanoemulsion presented a inserm-00709735, version 1 -19 Jun 2012 M a n u s c r i p t 18 negative zeta potential which is probably due to the anionic fractions of the employed lecithin (Wang et al., 2006) . 405 We have observed that fisetin nanoemulsion could exert its distinct morphological effects on endothelial cells similar to the free fisetin (Touil et al., 2009) indicating that fisetin could be released from its nanoemulsion formulation. These morphological changes on endothelial cells are attributed to a stabilization of the cytoskeleton as previously shown by increased acetylated alpha tubulin (Touil et al., 2009) . 410
Concerning the i.v. administration of the free fisetin and its nanoemulsion, we did not observe any pharmacokinetic difference, as expected for a classical emulsion, contrary to what is observed for a pegylated formulation which can increase the residence time (Reddy and Venkateswarlu, 2005) . As a matter of fact, upon injection of a classical emulsion, the particles interact with the apolipoproteins and are captured by the reticulo-endothelial system 415 leading to their rapid elimination from the blood compartment (Kawakami et al., 2000) . One possibility to increase the residence time using the i.v. administration would be to pegylate the emulsion that could increase the surface hydrophilic properties by forming a steric barrier that could result in a longer retention time in plasma (Tamilvanan, 2004 ).
We demonstrated that the i.p. administration of the fisetin nanoemulsion led to a 420 significant improvement in bioavailability compared to the i.p. administration of the free fisetin, with a 24-fold increase in relative bioavailability compared to the free fisetin administered via the same route. This could be due to a faster absorption phase from the peritoneal cavity with the nanoemulsion compared to free fisetin. As a matter of fact, the mean absorption time was shorter with the nanoemulsion (2 h) compared to the free fisetin (6 425 h). Similar results were reported for the hydrophobic taxoid paclitaxel where i.p.
administration was leading to a significant improvement in bioavailability compared to the i.v. administration (Soma et al., 2009 ). In addition, this enhanced bioavailability of the fisetin We also demonstrated that the fisetin nanoemulsion could elicit a significant antitumour activity in vivo in Lewis lung tumour bearing mice. It is noteworthy that a relatively low dose of the fisetin nanoemulsion corresponding to 36.6 mg/kg of fisetin was 435 able to reduce by 53% the tumour volume, whereas a 6-fold higher dose (223 mg/kg) was required to obtain a similar tumour growth inhibition with the free fisetin, as recently reported by Touil et al. (Touil et al., 2011) . This indicates that the nanoemulsion of fisetin is favourable to its anticancer action in vivo probably by increasing its bioavailability, as shown in this study. 440
Conclusion
In conclusion, we have developed a nanoemulsion of fisetin that allowed to solubilize a relatively high concentration of fisetin (5 mg/mL), thanks to the use of two surface active 445 agents, i.e., Tween ® 80 and Labrasol ® . However the latter agent appeared to be relatively toxic when using the i.v. route, but was not found toxic by the i.p. route. The developed fisetin nanoemulsion could also markedly increase the bioavailability of fisetin after i.p. 
